Article Details

Study Shows Real-World Outcomes of First-Line Palbociclib Plus Fulvestrant in HR+, HER2

Retrieved on: 2025-01-19 03:05:37

Tags for this article:

Click the tags to see associated articles and topics

Study Shows Real-World Outcomes of First-Line Palbociclib Plus Fulvestrant in HR+, HER2. View article details on hiswai:

Excerpt

Palbociclib (Ibrance; Pfizer) plus fulvestrant (Faslodex; AstraZeneca) as a first-line treatment for patients with hormone receptor-positive (HR+) ...

Article found on: www.pharmacytimes.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up